Skip to main content



FDA Approved Peptide for Weight Loss

What is Tirzepatide?
Tirzepatide is classified as a dual GIP/GLP-1 receptor Co=agonist, and mimics both GLP-1 and GIP hormones.  Tirzepatide has demonstrated significant weight loss effects in clinical trials and has shown superior weight reductions compared to other diabetes medications, including other GLP-1 receptor agonists. 

How does Tirzepatide work to help reduce body weight?
Tirzepatide lowers blood sugar levels by helping the pancreas release the right amount of insulin when blood sugar levels are high, which moves sugar from the blood into other body tissues where it is used for energy. Semaglutide injection also works by slowing the movement of food through the stomach and in most people decreases appetite and causes weight loss.

How will I use Tirzepatide?
Patients will receive one injection per week at NU Start for 4 consecutive weeks for the first month. Weekly appointments with an RN/Nutrition Consultant will be required during the first month. The length of Tirzepatide treatment will be determined in consultation by you and our medical staff.

What should I expect from my weekly appointment at NU Start?
Scheduled 15 minute appointments with an RN at Nustart will include directions for administration of the Tirzepatide, recommendations for diet and exercise, and instructions for management of possible side effects and adverse reactions. Vitamin B12 injections are included weekly in the first month and once a month thereafter. Body composition measurement is included at the beginning and end of treatment.

What is the cost of Tirzepatide treatment?
New patient cost is $475 and includes an InBody
Existing patients who have an InBody will be $450 for the first month of treatment. Continuous treatment $400 - $450 per month (depending on the number of visits/support needed)

What results can I expect while on Tirzepatide treatment?
Weight loss expectations average 5% of body weight in 3 months.
Weight loss expectations average 10-15% in 9 months.